LSBio

Bromodeoxyuridine (BrdU) is a thymidine analog that is selectively incorporated into the DNA of proliferating cells, providing a marker for DNA replication during the S-phase of the cell cycle. This allows for the easy quantification of actively proliferating cells in cell lysates, cell suspensions, and tissue sections, and provides additional information such as cell number, morphology, and cellular antigen analysis from a single culture. BrdU replaces traditional [3H] thymidine incorporation assays, eliminating the limitations of a slow, labor intensive procedure, expensive equipment, and the handling and disposal of radioisotopes. Our BrdU Immunohistochemistry Kit LS-K1085 can be used for staining in vivo BrdU labeled tissues (formalin-fixed paraffin-embedded (FFPE) or frozen sections), or in vitro labeled cultured cells. BrdU incorporated into newly synthesized DNA strands is detected using a biotinylated antibody, followed by a Streptavidin-HRP conjugate and visualization with DAB (diaminobenzidine) substrate and a Hematoxylin counter-stain.

Check out LSBio’s best-selling BrdU assay kit, offered in collaboration with Exalpha Biologicals:
https://www.lsbio.com/assaykits/brdu-immunohistochemistry-kit-ls-k1085/1085

Looking for personal protective equipment? Keep your workforce safe with LSBio’s catalog of high quality, affordable PPE.

You can minimize exposure to infectious viral particles and risk of hazardous liquid splashes with a variety of protective equipment. We offer KN95 masks, surgical masks, face shields, nitrile gloves, latex gloves, gowns, and more. Our masks have been independently tested and confirmed to meet the KN95 standard, effectively filtering 95% of airborne particles. Discounts are available for healthcare professionals and first responders.

Click here to explore our catalog of Researcher PPE https://www.lsbio.com/ppe

Need a different kind of PPE?
Email us [email protected]
Or call (206) 374-1102

A multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine, AZD1222, has begun. The vaccine was developed by Oxford University’s Jenner Institute and Oxford Vaccine Group and has been licensed to AstraZeneca, a United Kingdom-based global biopharmaceutical company, for further development. The vaccine uses a non-replicating chimpanzee adenovirus to deliver a SARS-CoV-2 spike protein to induce an immune response. The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States to evaluate if the candidate vaccine can prevent symptomatic COVID-19. The vaccine candidate will also be evaluated for its ability to prevent SARS-CoV-2 infection regardless of symptoms as well as preventing severe COVID-19 disease.

Click to read more on the Phase 3 clinical testing in the US of AstraZeneca COVID-19 Vaccine Candidate: https://www.nih.gov/news-events/news-releases/phase-3-clinical-testing-us-astrazeneca-covid-19-vaccine-candidate-begins